...
首页> 外文期刊>Annals of hematology >Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
【24h】

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.

机译:骨髓增生异常综合症,费城阴性骨髓增生性肿瘤和MDS / MPN重叠类别中细胞遗传学异常的分布。

获取原文
获取原文并翻译 | 示例

摘要

According to the new World Health Organization (WHO) classification (2008), chronic myeloid malignancies are divided in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and overlap MDS/MPN cases. From morphological aspects, these categories show overlaps. To evaluate whether these morphological similarities have genetic parallels, we investigated 1,851 cases with suspected/confirmed myelodysplastic or myeloproliferative diseases by chromosome banding and molecular analyses. Cytogenetics revealed aberrant karyotypes in 354 patients (19.1% of the original cohort) who were the basis of further analysis. The distribution of chromosomal aberrations differed significantly between categories. Isolated +9 and gain of 9p were exclusively observed in MPN (+9: 10/93; 11%; p < 0.001; +9p: 6/93; 7% of all aberrant MPN cases) but were not detected in MDS or MDS/MPN (p = 0.001). Isolated del(5q) (p = 0.002), -7 in combination with other aberrations (p = 0.016), and complex aberrations (p = 0.003) were 2.9- to 7.5-fold more frequent in MDS than in MPN. Trisomies 8 and 21 and del(20q) were comparably frequent in both subgroups. Interestingly, the MDS/MPN overlap cohort showed a higher frequency of -7 accompanied by other aberrations (3/17; 18% of all aberrant cases; p = 0.001), i(17)(q10) (2/17; 12%; p = 0.013), and +21 (2/17; 12%; p = 0.013) when compared to MPN or MDS only. These differences support the category for MDS/MPN within the new WHO classification. Overlaps between the diverse disorders were seen also for the JAK2V617F (MPN 66/89; 74%; MDS/MPN 4/14; 29%; MDS 2/63; 3%) and NRAS mutations (MDS 2/67; 3%; MPN 2/4; MDS/MPN 1/1). In conclusion, cytogenetics and molecular genetics show overlaps in varying proportions of MDS and MPN cases which might indicate common pathways in their etiology. Some markers are strongly associated with one of these disorders and can be helpful for differential diagnosis especially in difficult cases.
机译:根据新的世界卫生组织(WHO)分类(2008年),慢性骨髓性恶性肿瘤分为骨髓增生性肿瘤(MPN),骨髓增生异常综合症(MDS)和MDS / MPN重叠病例。从形态方面来看,这些类别显示出重叠。为了评估这些形态相似性是否具有遗传相似性,我们通过染色体显带和分子分析调查了1851例疑似/确诊的骨髓增生异常或骨髓增生性疾病病例。细胞遗传学揭示了354例患者的异常核型,这是进一步分析的基础。类别之间的染色体畸变的分布差异很大。在MPN中仅观察到孤立的+9和9p的增益(+9:10/93; 11%; p <0.001; + 9p:6/93;所有异常MPN病例的7%),但在MDS或MDS中未检测到/ MPN(p = 0.001)。在MDS中,孤立的del(5q)(p = 0.002),-7与其他像差(p = 0.016)和复杂像差(p = 0.003)组合的发生频率是MPN的2.9-7.5倍。在两个亚组中,三体8和21和del(20q)的发生率相对较高。有趣的是,MDS / MPN重叠队列显示出较高的-7频率并伴有其他畸变(3/17;占所有异常病例的18%; p = 0.001),i(17)(q10)(2/17; 12% ;仅与MPN或MDS相比,p = 0.013)和+21(2/17; 12%; p = 0.013)。这些差异支持新的WHO分类中的MDS / MPN类别。 JAK2V617F(MPN 66/89; 74%; MDS / MPN 4/14; 29%; MDS 2/63; 3%)和NRAS突变(MDS 2/67; 3%; 5%)出现了多种疾病之间的重叠。 MPN 2/4; MDS / MPN 1/1)。总之,细胞遗传学和分子遗传学在MDS和MPN病例的不同比例上有重叠,这可能表明它们的病因有共同的途径。一些标志物与这些疾病之一密切相关,可以帮助鉴别诊断,特别是在困难的情况下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号